LENZ Therapeutics, Inc. Quarterly Debt-to-equity in % from Q1 2022 to Q2 2024

Taxonomy & unit: ratio: %
Description: Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary: LENZ Therapeutics, Inc. quarterly Debt-to-equity history and growth rate from Q1 2022 to Q2 2024.
LENZ Therapeutics, Inc. Debt-to-equity for the quarter ending June 30, 2024 was 22.1 %, a 68% decline year-over-year.

Debt-to-equity, Quarterly (%)

Debt-to-equity, YoY Quarterly Growth (%)

Period	Value	YoY Chg	Change %	Date
Q2 2024	22.1	-46.8	-68%	Jun 30, 2024
Q1 2024	63.5	+47.8	+305%	Mar 31, 2024
Q4 2023	763	+755	+9770%	Dec 31, 2023
Q3 2023	201	+196	+3973%	Sep 30, 2023
Q2 2023	68.8	+64.3	+1434%	Jun 30, 2023
Q1 2023	15.7	+11.8	+304%	Mar 31, 2023
Q4 2022	7.73			Dec 31, 2022
Q3 2022	4.93			Sep 30, 2022
Q2 2022	4.49			Jun 30, 2022
Q1 2022	3.88			Mar 31, 2022

* An asterisk sign (*) next to the value indicates that the value is likely invalid.